Epidemiologia das infecções por rotavírus no Brasil e os desafios para o seu controle
Autor(a) principal: | |
---|---|
Data de Publicação: | 2000 |
Tipo de documento: | Artigo |
Idioma: | por |
Título da fonte: | Cadernos de Saúde Pública |
Texto Completo: | https://cadernos.ensp.fiocruz.br/ojs/index.php/csp/article/view/1390 |
Resumo: | Worldwide, rotaviruses account for 600,000 to 870,000 deaths per year among infants and young children. In Brazil, rotaviruses were first seen in 1976 by scanning electron microscopy of stool samples from diarrheic infants in Belém, Pará. Hospital-based studies have shown that rotaviruses are associated with 12-42% of cases of acute diarrhea. In addition, community-based studies yielded an average of 0.25 rotavirus-related diarrheal episodes per child per year. G types 1 to 4 account for about two-thirds of circulating strains, but the (unusual) P[8],G5 genotype has been claimed to cause over 10% of rotavirus diarrheal episodes. It has been shown that over 70% of children develop rotavirus antibodies by the age of 4-5 years. The tetravalent rhesus-human rotavirus vaccine (RRV-TV) conferred 35% protection according to a two-year follow-up study in Belém, Pará, Brazil, but reached an efficacy of 60% during the first year of life. RRV-TV was also shown to be 75% protective against very severe gastroenteritis in northern Brazil. Vaccination with RRV-TV has been suspended recently in the United States because of the detection of intussusception as a side effect. Therefore, further vaccine trials in Brazil will probably involve rotavirus candidate vaccines other than RRV-TV. |
id |
FIOCRUZ-5_28fa74d7c7677b9ecfd935fb2db42c49 |
---|---|
oai_identifier_str |
oai:ojs.teste-cadernos.ensp.fiocruz.br:article/1390 |
network_acronym_str |
FIOCRUZ-5 |
network_name_str |
Cadernos de Saúde Pública |
repository_id_str |
|
spelling |
Epidemiologia das infecções por rotavírus no Brasil e os desafios para o seu controleRotavírusControleEpidemiologiaWorldwide, rotaviruses account for 600,000 to 870,000 deaths per year among infants and young children. In Brazil, rotaviruses were first seen in 1976 by scanning electron microscopy of stool samples from diarrheic infants in Belém, Pará. Hospital-based studies have shown that rotaviruses are associated with 12-42% of cases of acute diarrhea. In addition, community-based studies yielded an average of 0.25 rotavirus-related diarrheal episodes per child per year. G types 1 to 4 account for about two-thirds of circulating strains, but the (unusual) P[8],G5 genotype has been claimed to cause over 10% of rotavirus diarrheal episodes. It has been shown that over 70% of children develop rotavirus antibodies by the age of 4-5 years. The tetravalent rhesus-human rotavirus vaccine (RRV-TV) conferred 35% protection according to a two-year follow-up study in Belém, Pará, Brazil, but reached an efficacy of 60% during the first year of life. RRV-TV was also shown to be 75% protective against very severe gastroenteritis in northern Brazil. Vaccination with RRV-TV has been suspended recently in the United States because of the detection of intussusception as a side effect. Therefore, further vaccine trials in Brazil will probably involve rotavirus candidate vaccines other than RRV-TV.Os rotavírus causam de 600.000 a 870.000 óbitos por ano entre crianças em todo o mundo. Esses vírus foram visualizados pela primeira vez no Brasil em 1976, a partir da microscopia eletrônica das fezes de crianças diarréicas em Belém, Pará. Estudos conduzidos em hospitais registraram prevalência de diarréia por rotavírus de 12% e 42%. A par disso, investigações longitudinais assinalaram taxa média de 0,25 episódio de diarréia por criança/ano. Os tipos G1, G2, G3 e G4 representam cerca de 2/3 das amostras circulantes, porém, sustenta-se que o genótipo P[8], G5 associa-se a, no mínimo, 10% das diarréias. Estudos sobre a imunidade natural para rotavírus revelaram que 70% das crianças adquirem anticorpos já aos 4-5 anos de idade. A vacina tetravalente, de origem símio-humana (RRV-TV) conferiu proteção de 35% após dois anos de estudo; contudo, o nível protetor alcançou 60% no primeiro ano de vida. A RRV-TV, no norte do Brasil, revelou eficácia de 75% frente às diarréias graves. Há poucos meses interrompeu-se o uso dessa vacina nos EUA devido à ocorrência de intussuscepção como efeito colateral. É provável que futuros experimentos no Brasil contemplem outras "candidatas" a vacina contra rotavírus, que não a RRV-TV.Reports in Public HealthCadernos de Saúde Pública2000-09-01info:eu-repo/semantics/articleinfo:eu-repo/semantics/publishedVersiontext/htmlapplication/pdfhttps://cadernos.ensp.fiocruz.br/ojs/index.php/csp/article/view/1390Reports in Public Health; Vol. 16 No. 3 (2000): July/SeptemberCadernos de Saúde Pública; v. 16 n. 3 (2000): Julho/Setembro1678-44640102-311Xreponame:Cadernos de Saúde Públicainstname:Fundação Oswaldo Cruz (FIOCRUZ)instacron:FIOCRUZporhttps://cadernos.ensp.fiocruz.br/ojs/index.php/csp/article/view/1390/2768https://cadernos.ensp.fiocruz.br/ojs/index.php/csp/article/view/1390/2769Linhares, Alexandre C.info:eu-repo/semantics/openAccess2024-03-06T15:26:24Zoai:ojs.teste-cadernos.ensp.fiocruz.br:article/1390Revistahttps://cadernos.ensp.fiocruz.br/ojs/index.php/csphttps://cadernos.ensp.fiocruz.br/ojs/index.php/csp/oaicadernos@ensp.fiocruz.br||cadernos@ensp.fiocruz.br1678-44640102-311Xopendoar:2024-03-06T13:01:40.022160Cadernos de Saúde Pública - Fundação Oswaldo Cruz (FIOCRUZ)true |
dc.title.none.fl_str_mv |
Epidemiologia das infecções por rotavírus no Brasil e os desafios para o seu controle |
title |
Epidemiologia das infecções por rotavírus no Brasil e os desafios para o seu controle |
spellingShingle |
Epidemiologia das infecções por rotavírus no Brasil e os desafios para o seu controle Linhares, Alexandre C. Rotavírus Controle Epidemiologia |
title_short |
Epidemiologia das infecções por rotavírus no Brasil e os desafios para o seu controle |
title_full |
Epidemiologia das infecções por rotavírus no Brasil e os desafios para o seu controle |
title_fullStr |
Epidemiologia das infecções por rotavírus no Brasil e os desafios para o seu controle |
title_full_unstemmed |
Epidemiologia das infecções por rotavírus no Brasil e os desafios para o seu controle |
title_sort |
Epidemiologia das infecções por rotavírus no Brasil e os desafios para o seu controle |
author |
Linhares, Alexandre C. |
author_facet |
Linhares, Alexandre C. |
author_role |
author |
dc.contributor.author.fl_str_mv |
Linhares, Alexandre C. |
dc.subject.por.fl_str_mv |
Rotavírus Controle Epidemiologia |
topic |
Rotavírus Controle Epidemiologia |
description |
Worldwide, rotaviruses account for 600,000 to 870,000 deaths per year among infants and young children. In Brazil, rotaviruses were first seen in 1976 by scanning electron microscopy of stool samples from diarrheic infants in Belém, Pará. Hospital-based studies have shown that rotaviruses are associated with 12-42% of cases of acute diarrhea. In addition, community-based studies yielded an average of 0.25 rotavirus-related diarrheal episodes per child per year. G types 1 to 4 account for about two-thirds of circulating strains, but the (unusual) P[8],G5 genotype has been claimed to cause over 10% of rotavirus diarrheal episodes. It has been shown that over 70% of children develop rotavirus antibodies by the age of 4-5 years. The tetravalent rhesus-human rotavirus vaccine (RRV-TV) conferred 35% protection according to a two-year follow-up study in Belém, Pará, Brazil, but reached an efficacy of 60% during the first year of life. RRV-TV was also shown to be 75% protective against very severe gastroenteritis in northern Brazil. Vaccination with RRV-TV has been suspended recently in the United States because of the detection of intussusception as a side effect. Therefore, further vaccine trials in Brazil will probably involve rotavirus candidate vaccines other than RRV-TV. |
publishDate |
2000 |
dc.date.none.fl_str_mv |
2000-09-01 |
dc.type.driver.fl_str_mv |
info:eu-repo/semantics/article info:eu-repo/semantics/publishedVersion |
format |
article |
status_str |
publishedVersion |
dc.identifier.uri.fl_str_mv |
https://cadernos.ensp.fiocruz.br/ojs/index.php/csp/article/view/1390 |
url |
https://cadernos.ensp.fiocruz.br/ojs/index.php/csp/article/view/1390 |
dc.language.iso.fl_str_mv |
por |
language |
por |
dc.relation.none.fl_str_mv |
https://cadernos.ensp.fiocruz.br/ojs/index.php/csp/article/view/1390/2768 https://cadernos.ensp.fiocruz.br/ojs/index.php/csp/article/view/1390/2769 |
dc.rights.driver.fl_str_mv |
info:eu-repo/semantics/openAccess |
eu_rights_str_mv |
openAccess |
dc.format.none.fl_str_mv |
text/html application/pdf |
dc.publisher.none.fl_str_mv |
Reports in Public Health Cadernos de Saúde Pública |
publisher.none.fl_str_mv |
Reports in Public Health Cadernos de Saúde Pública |
dc.source.none.fl_str_mv |
Reports in Public Health; Vol. 16 No. 3 (2000): July/September Cadernos de Saúde Pública; v. 16 n. 3 (2000): Julho/Setembro 1678-4464 0102-311X reponame:Cadernos de Saúde Pública instname:Fundação Oswaldo Cruz (FIOCRUZ) instacron:FIOCRUZ |
instname_str |
Fundação Oswaldo Cruz (FIOCRUZ) |
instacron_str |
FIOCRUZ |
institution |
FIOCRUZ |
reponame_str |
Cadernos de Saúde Pública |
collection |
Cadernos de Saúde Pública |
repository.name.fl_str_mv |
Cadernos de Saúde Pública - Fundação Oswaldo Cruz (FIOCRUZ) |
repository.mail.fl_str_mv |
cadernos@ensp.fiocruz.br||cadernos@ensp.fiocruz.br |
_version_ |
1816705346370011136 |